Sublingual Semaglutide Drops: What the Absorption Evidence Shows
There is no FDA-approved sublingual semaglutide, and a 2026 review in the Annals of Pharmacotherapy found no published human pharmacokinetic data comparing compounded sublingual products with the approved tablets or injections. The best comparison point is FDA-approved oral semaglutide, and its label is sobering: even with a purpose-built absorption enhancer and strict fasting rules, only about 0.4% to 2% of the swallowed dose is absorbed, versus 89% for the injection.
Key takeaways
- FDA-approved semaglutide comes in two routes only: under-the-skin injection and swallowed tablets. Neither drops nor troches are approved.
- Approved tablets rely on SNAC, an absorption enhancer, and still reach an estimated absolute bioavailability of just 0.4% to 2%, depending on the formulation.
- To get the effect of a 2.4 mg weekly Wegovy injection, the Wegovy pill uses 25 mg every day, roughly 70 times more drug by weight per week.
- Compounded drugs are not reviewed by FDA for safety, effectiveness or quality, and FDA says it knows of no lawful basis for compounding with semaglutide salt forms.
- Without published human blood-level data, there is no verified way to know what dose a sublingual product delivers. The supporting studies so far are in animals.
What's approved, and how well each form is absorbed
Absolute bioavailability is the share of a dose that reaches the bloodstream. It is the single most useful number for judging a non-injected peptide, and FDA labels report it for every approved semaglutide product.
| Product | Route | Dosing on the label | Estimated absolute bioavailability |
|---|---|---|---|
| Ozempic injection | Subcutaneous | 0.5 mg, 1 mg or 2 mg once weekly (maintenance) | 89% |
| Wegovy injection | Subcutaneous | 2.4 mg once weekly; up to 7.2 mg for weight reduction in some patients | 89% |
| Rybelsus tablets | Oral | 3, 7 or 14 mg once daily | About 0.4% to 1% |
| Ozempic tablets | Oral | 1.5, 4 or 9 mg once daily | About 1% to 2% |
| Wegovy tablets | Oral | 25 mg once daily (maintenance) | About 1% to 2% |
| Compounded sublingual drops or troches | Under the tongue or dissolved in the mouth | Not FDA-approved; no label | No published human data |
Source: Ozempic prescribing information (revised 05/2026), Wegovy injection and tablets prescribing information (revised 06/2026), Rybelsus and Ozempic tablets prescribing information (revised 01/2026).
The gap between 89% and 1% is the core of this topic. Semaglutide is a large peptide, with a molecular weight of 4,113.58 g/mol according to the Ozempic label. Molecules that size do not cross the lining of the mouth or gut easily, and stomach enzymes and acid break peptides down.
How the approved pill gets any semaglutide in at all
Novo Nordisk did not simply press semaglutide into a tablet. The approved tablets are co-formulated with SNAC (salcaprozate sodium). The label states that the tablets "are co-formulated with SNAC which facilitates the absorption of semaglutide after oral administration" (Rybelsus and Ozempic tablets label).
Even with SNAC, absorption is fragile. The label instructs patients to take the tablet on an empty stomach in the morning with no more than 4 ounces of water and to wait at least 30 minutes before eating. It reports that absorption was higher with 50 mL of water than with 240 mL, and higher with a longer fasting period after the dose (label). The Wegovy tablets carry the same type of instructions (Wegovy label).
The dose math shows the cost of oral delivery. Wegovy tablets reach a 25 mg daily maintenance dose, or 175 mg a week, while the Wegovy injection's standard maintenance dose is 2.4 mg a week (Wegovy label). That is roughly 70 times more drug by weight to work through the gut. FDA approved the Wegovy pill in December 2025, and the 25 mg dose produced an average weight loss of 16.6% in the OASIS 4 trial (pharmaphorum). Our separate OASIS coverage goes deeper on those trials.
Want a needle-free option with data behind it?
FDA-approved oral semaglutide has a label, trial results and known absorption numbers.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
What the evidence says about sublingual semaglutide
No published human blood-level data
The question patients need answered is simple: if you hold a semaglutide drop under your tongue, how much ends up in your blood? Answering it takes a pharmacokinetic study that measures blood levels over time. For the approved tablets, those studies are why the label can state a bioavailability range.
For compounded sublingual products, that work has not been published. A review by Belcourt, Sapowadia and White, published online in February 2026, looked at 33 compounded semaglutide and tirzepatide products marketed online that differed from the approved versions. Of the 17 single-ingredient products, 82% were sublingual. The authors found no published human pharmacokinetic data comparing sublingual or orally disintegrating forms with the approved oral or injectable products, and no studies measuring weight loss or safety, so the correct dose is unknown (Annals of Pharmacotherapy, 2026). The only supporting data they cited came from a mouse study.
That is an absence of human evidence, not proof the products deliver nothing. But it means any dose a seller assigns to a sublingual product, such as "equivalent to" an injected dose, is not backed by published human data.
Why the oral data cut against sublingual claims
The approved labels attribute oral absorption to SNAC working under tightly controlled conditions. A compounded drop or troche is a different formulation. Some of the dose is likely to be swallowed with saliva, where it would face the gut without the conditions the approved label describes. Whether a particular product contains any absorption enhancer, and whether that enhancer works in the mouth, is unknown unless the maker has tested it. This is reasoning from the approved product's data, not a measured result for any sublingual product.
FDA's position on compounded, non-approved forms
FDA's main GLP-1 consumer page, current as of October 1, 2026, does not single out sublingual products. Its general statements still apply directly.
- No premarket review. FDA states that compounded drugs are not FDA-approved and that the agency does not review them for safety, effectiveness or quality before they are marketed (FDA).
- Salt forms. FDA says semaglutide sodium and semaglutide acetate "are different active ingredients than are used in the approved drugs," that it does not know whether they share the same chemical and pharmacologic properties, and that it is not aware of any lawful basis for their use in compounding (FDA).
- Route and "essentially a copy." FDA's 2018 guidance for 503A pharmacies treats the route of administration as one factor in deciding whether a compounded drug is essentially a copy of an approved one, and allows changes that a prescriber determines will make a significant difference for that patient, documented on the prescription. FDA adds that factors such as "a lower price" are not enough (FDA guidance).
The legal analysis and the scientific one are separate questions. Whether a pharmacy may lawfully make a sublingual product under 503A does not tell you whether the product works. FDA's guidance governs what a pharmacy can make, and it does not establish that the product delivers a meaningful dose.
| Question | Approved oral semaglutide | Compounded sublingual semaglutide |
|---|---|---|
| FDA review of safety, effectiveness and quality | Yes | No |
| Absorption enhancer documented | Yes, SNAC | Unknown unless the maker discloses and tests it |
| Bioavailability published on a label | Yes, about 0.4% to 2% | No |
| Phase 3 weight or glucose outcomes | Yes | None published |
| Active ingredient form specified by FDA | Yes | May be base or a salt form FDA says lacks a lawful basis |
Source: Rybelsus and Ozempic tablets label, Wegovy label, FDA. Outcome and absorption gaps for sublingual products per Belcourt et al., Annals of Pharmacotherapy, 2026.
Questions to ask before using a drop or troche
If a prescriber or pharmacy offers a sublingual product, these questions get at the evidence gap:
- Is the active ingredient semaglutide base or a salt form such as semaglutide sodium or acetate?
- Is there any human blood-level data for this specific formulation, and can I see it?
- What is the stated dose based on, and how does it compare with an approved product?
- Does the product contain an absorption enhancer, and has it been tested in the mouth?
- What will we measure, such as weight or A1C, to decide whether it is working?
The bottom line
The approved oral semaglutide story is a story about how hard this molecule is to absorb without a needle. It took a dedicated absorption enhancer, fasting rules and roughly 70 times the weekly drug amount for the pill to match the injection's results. Compounded drops and troches have none of that published groundwork. If avoiding injections is your priority, ask your prescriber whether an FDA-approved tablet fits your situation, since its absorption and outcomes are documented.
Compare pills and pens
See current pricing for FDA-approved oral and injectable GLP-1 treatments.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Frequently asked questions
Is sublingual semaglutide FDA-approved?
No. FDA-approved semaglutide comes only as subcutaneous injections (Ozempic, Wegovy) and swallowed tablets (Rybelsus, Ozempic tablets, Wegovy tablets). Drops and troches are compounded products that FDA has not reviewed.
How much oral semaglutide is actually absorbed?
FDA labels estimate absolute bioavailability of about 0.4% to 1% for Rybelsus and about 1% to 2% for Ozempic and Wegovy tablets, compared with 89% for the injection.
Is there research showing sublingual semaglutide drops work?
Not in humans. A 2026 review in the Annals of Pharmacotherapy found no published human pharmacokinetic data comparing compounded sublingual products with approved semaglutide, and no studies of their weight-loss or safety outcomes. Supporting data so far come from animal studies.
Why does the approved semaglutide pill need SNAC?
The label says the tablets are co-formulated with SNAC, which facilitates semaglutide absorption after oral administration. Even so, absorption depends on an empty stomach, limited water and a 30-minute wait before eating.
Sources
- Rybelsus and Ozempic (semaglutide) tablets prescribing information, revised 01/2026
- Wegovy (semaglutide) injection and tablets prescribing information, revised 06/2026
- Ozempic (semaglutide) injection prescribing information, revised 05/2026
- pharmaphorum: Novo Nordisk gets FDA okay for Wegovy pill (Dec. 23, 2025)
- FDA: FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- FDA guidance: Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A (January 2018)
- Belcourt J, Sapowadia A, White CM. Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown. Ann Pharmacother. 2026
Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.